key: cord-0313124-8rgt93ff
authors: Cele, S.; Bernstein, M.; Karim, F.; Khan, K.; Ganga, Y.; Jule, Z.; Reedoy, K.; Lustig, G.; Samsunder, N.; Mazibuko, M.; Hwa, S.-H.; Manickchund, N.; Magula, N.; Lessells, R.; de Oliveira, T.; Karim, S. A.; Hanekom, W.; COMMIT-KZN Team,; Gosnell, B.; Moosa, Y.; Sigal, A.
title: Beta infection combined with Pfizer BNT162b2 vaccination leads to broadened neutralizing immunity against Omicron
date: 2022-04-15
journal: nan
DOI: 10.1101/2022.04.15.22273711
sha: 316e53609e5781417181b3dcb9ef074e40b83e32
doc_id: 313124
cord_uid: 8rgt93ff

Omicron (B.1.1.529) shows extensive escape from vaccine immunity, although vaccination reduces severe disease and death. Boosting with vaccines incorporating variant spike sequences could possibly broaden immunity. One approach to choose the variant may be to measure immunity elicited by vaccination combined with variant infection. Here we investigated Omicron neutralization in people infected with the Beta (B.1.351) variant and subsequently vaccinated with Pfizer BNT162b2. We observed that Beta infection alone elicited poor Omicron cross-neutralization, similar to what we previously found with BNT162b2 vaccination alone or in combination with ancestral or Delta virus infection. In contrast, Beta infection combined with BNT162b2 vaccination elicited neutralization with substantially lower Omicron escape.

reduces severe disease and death 1 . Boosting with vaccines incorporating variant spike sequences could possibly broaden immunity 2 . One approach to choose the variant may be to measure immunity elicited by vaccination combined with variant infection. Here we investigated Omicron neutralization in people infected with the Beta (B.1.351) variant and subsequently vaccinated with Pfizer BNT162b2. We observed that Beta infection alone elicited poor Omicron cross-neutralization, similar to what we previously found 3 with BNT162b2 vaccination alone or in combination with ancestral or Delta virus infection. In contrast, Beta infection combined with BNT162b2 vaccination elicited neutralization with substantially lower Omicron escape.

South Africa had a Beta dominated infection wave November 2020 to May 2021 4 . We enrolled 18 Beta infected participants based on infection date who were later vaccinated with Pfizer BNT162b2 (Table S1) . A pre-vaccine sample was taken a median of 29 days post-symptom onset, and a post-vaccine sample 31 days post-vaccination. Five participants received one vaccine dose and the others two doses. None were boosted.

We measured plasma neutralization capacity as FRNT 50 using live virus neutralization. Postvaccination, Beta virus neutralization increased 21.3-fold (95% CI 9.7-46.8, Fig 1a) from geometric mean titer (GMT) FRNT 50 of 112 to 2385. Omicron/BA.1 FRNT 50 pre-vaccination was 6, rising post-vaccination 69.3-fold (95% CI 32.0-150, Fig 1b) Fig 1c) , confirming previous results 5 . Because many pre-vaccination samples did not reach 50% BA.1 neutralization with the most concentrated plasma tested, we tested additional samples from Beta infected individuals and obtained similar results (19.2-fold escape, Fig S1) . In contrast, the fold-drop between Beta and Omicron/BA.1 neutralization post-vaccination was 5.3-fold (95% CI 4.4-6.4, Fig 1d) . Hence, Omicron/BA.1 escape was reduced more than 3-fold. Similarly to BA.1, cross-neutralization of Omicron/BA.2 post-. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 15, 2022. ; vaccination was only 4.2-fold lower (95% CI 3.4-5.2, Fig 1e) . Ancestral virus neutralization showed a 1.5-fold decline relative to Beta (95% CI 1.2-1.8, Fig 1f) .

These results contrast with our previous findings for BNT162b2 vaccination alone or in combination with ancestral or Delta virus infection, where we observed approximately 20-fold drops in Omicron neutralization 3 . The limitations are that here we tested immunity generated by Beta virus infection followed by vaccination. Whether boosting with Beta sequence postprimary vaccination would be similar is unclear. However, it may be one line of evidence which argues for testing this approach. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

Cele et al. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 15, 2022. ; https://doi.org/10.1101/2022.04.15.22273711 doi: medRxiv preprint Live virus neutralization assay H1299-E3 cells were plated in a 96-well plate (Corning) at 30,000 cells per well 1 day preinfection. Plasma was separated from EDTA-anticoagulated blood by centrifugation at 500 rcf for 10 min and stored at −80 °C. Aliquots of plasma samples were heat-inactivated at 56 °C for 30 min and clarified by centrifugation at 10,000 rcf for 5 min. Virus stocks were used at approximately 50-100 focus-forming units per microwell and added to diluted plasma.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 15, 2022. ;

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

This study was supported by the Bill and Melinda Gates award INV-018944 (AS), National Institutes of Health award R01 AI138546 (AS), and South African Medical Research Council award 6084COAP2020 (AS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Antibody-virus mixtures were incubated for 1 h at 37 °C, 5% CO 2 . Cells were infected with 100 μL of the virus-antibody mixtures for 1 h, then 100 μL of a 1X RPMI 1640 (Sigma-Aldrich, R6504), 1.5% carboxymethylcellulose (Sigma-Aldrich, C4888) overlay was added without removing the inoculum. Cells were fixed 18 h post-infection using 4% PFA (Sigma-Aldrich) for 20 min. Foci were stained with a rabbit anti-spike monoclonal antibody (BS-R2B12, GenScript A02058) at 0.5 μg/mL in a permeabilization buffer containing 0.1% saponin (Sigma-Aldrich), 0.1% BSA (Sigma-Aldrich) and 0.05% Tween-20 (Sigma-Aldrich) in PBS. Plates were incubated with primary antibody overnight at 4 °C, then washed with wash buffer containing 0.05% Tween-20 in PBS. Secondary goat anti-rabbit HRP conjugated antibody (Abcam ab205718) was added at 1 μg/mL and incubated for 2 h at room temperature with shaking. TrueBlue peroxidase substrate (SeraCare 5510-0030) was then added at 50 μL per well and incubated for 20 min at room temperature. Plates were imaged in an ImmunoSpot Ultra-V S6-02-6140 Analyzer ELISPOT instrument with BioSpot Professional built-in image analysis (C.T.L).

All statistics and fitting were performed using custom code in MATLAB v.2019b. Neutralization data were fit to:Here Tx is the number of foci normalized to the number of foci in the absence of plasma on the same plate at dilution D and ID 50 is the plasma dilution giving 50% neutralization. FRNT 50 = 1/ID 50 . Values of FRNT 50 <1 are set to 1 (undiluted), the lowest measurable value. We note that the most concentrated plasma dilution was 1:10 for experiments with weak neutralization (pre-vaccine samples) and therefore FRNT 50 < 10 were extrapolated. To calculate confidence intervals, FRNT 50 or fold-change in FRNT 50 per participant was log transformed and arithmetic mean + 2 std and arithmetic mean -2 std were calculated for the log transformed values. These were exponentiated to obtain the upper and lower 95% confidence intervals on the geometric mean FRNT 50 or the fold-change in FRNT 50 geometric means.

Figure S1: Omicron escape in participants with Omicron neutralization greater than FRNT 50 =10. For this analysis, participant samples pre-vaccination (n=8, participant numbers 1, 5, 6, 12, 13, 14, 17, 18 according to Table S2 ) were selected based at least 50% Omicron/BA.1 neutralization at the most concentrated plasma used (1:10 dilution, corresponding to FRNT 50 =10 shown by dashed horizontal line). In addition, n=8 samples from unvaccinated participants infected in the Beta infection wave in South Africa were selected solely on FRNT 50 >10 for Omicron/BA.1 neutralization (participants 19-26 listed on Table S3 ). Data points are geometric means of FRNT 50 measurements from two independent experiments performed on different days. p-value was 7.7x10 -7 as determined by the Wilcoxon rank sum test and fold-change 95% confidence intervals were 14.1 to 28.1-fold.